0000950170-24-010798.txt : 20240202
0000950170-24-010798.hdr.sgml : 20240202
20240202190343
ACCESSION NUMBER: 0000950170-24-010798
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240130
FILED AS OF DATE: 20240202
DATE AS OF CHANGE: 20240202
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Simpson Adam K.
CENTRAL INDEX KEY: 0001873839
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40655
FILM NUMBER: 24593446
MAIL ADDRESS:
STREET 1: C/O ICOSAVAX, INC.
STREET 2: 1616 EASTLAKE AVENUE E., SUITE 208
CITY: SEATTLE
STATE: WA
ZIP: 98102
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Icosavax, Inc.
CENTRAL INDEX KEY: 0001786255
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1930 BOREN AVE., SUITE 1000
CITY: SEATTLE
STATE: WA
ZIP: 98101
BUSINESS PHONE: (206) 737-0085
MAIL ADDRESS:
STREET 1: 1930 BOREN AVE., SUITE 1000
CITY: SEATTLE
STATE: WA
ZIP: 98101
4
1
ownership.xml
4
X0508
4
2024-01-30
0001786255
Icosavax, Inc.
ICVX
0001873839
Simpson Adam K.
C/O ICOSAVAX, INC.
1930 BOREN AVE., SUITE 1000
SEATTLE
WA
98101
true
true
false
false
Chief Executive Officer
true
Common Stock
2024-02-01
4
G
false
6532
0
D
525044
I
By family trust
Common Stock
2024-02-01
4
M
false
15000
1.04
A
373657
D
Common Stock
2024-02-01
4
S
false
15000
15.2924
D
358657
D
Common Stock
129032
I
By family trust
Common Stock
129032
I
By family trust
Stock Option (Right to Buy)
1.04
2024-02-01
4
M
false
15000
0.00
D
2031-01-28
Common Stock
15000
191449
D
The sales were effected pursuant to a Rule 10b5-1 instruction letter dated September 16, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.28 to $15.31. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
25% of the shares subject to the option vested on January 14, 2022, and 1/48th of the shares subject to the option vest monthly thereafter.
/s/ Elizabeth Bekiroglu, Attorney-in-Fact
2024-02-02